

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

ETAS ID: TM372205

SUBMISSION TYPE:	NEW ASSIGNMENT		
NATURE OF CONVEYANCE:	RELEASE OF SECURITY INTEREST		
CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
SWK FUNDING LLC		02/05/2016	LIMITED LIABILITY COMPANY: DELAWARE
RECEIVING PARTY DATA			
Name:	TRIBUTE PHARMACEUTICALS CANADA, INC.		
Street Address:	544 EGERTON STREET		
Internal Address:	COUNTY OF MIDDLESEX		
City:	ON		
State/Country:	CANADA		
Postal Code:	N5W 3Z8		
Entity Type:	CORPORATION: CANADA		
PROPERTY NUMBERS Total: 3			
Property Type	Number	Word Mark	
Serial Number:	86006574	TRIBUTE PHARMACEUTICALS	
Serial Number:	86006569	TRIBUTE PHARMACEUTICALS	
Registration Number:	2677199	URACYST	
CORRESPONDENCE DATA			
Fax Number:	4048853900		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
Phone:	4048853868		
Email:	rusty.close@troutmansanders.com		
Correspondent Name:	CHRISTOPHER CLOSE		
Address Line 1:	TROUTMAN SANDERS LLP		
Address Line 2:	600 PEACHTREE STREET NE, SUITE 5200		
Address Line 4:	ATLANTA, GEORGIA 30308-2216		
ATTORNEY DOCKET NUMBER:	245360.000015		
NAME OF SUBMITTER:	Christopher Close		
SIGNATURE:	/Christopher Close/		
DATE SIGNED:	02/05/2016		
Total Attachments: 5			

CH \$90.00 86006574

source=Tribute IP Security Release Agreement (Executed)#page1.tif
source=Tribute IP Security Release Agreement (Executed)#page2.tif
source=Tribute IP Security Release Agreement (Executed)#page3.tif
source=Tribute IP Security Release Agreement (Executed)#page4.tif
source=Tribute IP Security Release Agreement (Executed)#page5.tif

RELEASE OF SECURITY INTEREST IN INTELLECTUAL PROPERTY

THIS RELEASE OF SECURITY INTEREST IN INTELLECTUAL PROPERTY (this "Release") is made as of the 5th day of February, 2016, by SWK FUNDING LLC, a Delaware limited liability company ("Assignor") in favor of TRIBUTE PHARMACEUTICALS CANADA, INC., TRIBUTE PHARMACEUTICALS US INC., and TRIBUTE PHARMACEUTICALS INTERNATIONAL, INC. (collectively, "Assignee"), and.

WHEREAS, pursuant to the terms and conditions of that certain Security Agreement dated as of August 8, 2013 by and between Assignee and Assignor (as the same may have been amended, restated, supplemented, or otherwise modified from time to time, the "Security Agreement"; capitalized terms used herein without definition shall have the meanings set forth in the Security Agreement), Assignee granted, and/or reaffirmed its prior grant, pursuant to the loan agreement, to Assignor, for its benefit and the benefit of the Lenders, among other things, a continuing security interest in Assignee's entire right, title and interest in and to any and all patents and trademarks located in the United States owned by Assignee including, but not limited to, those patents and trademarks listed on Exhibit A attached hereto (the "Released Intellectual Property"); and

WHEREAS, Assignor has agreed to release its security interest in the Released Intellectual Property.

NOW, THEREFORE, for valuable consideration and pursuant to the terms and conditions set forth in the Agreements:

Assignor hereby terminates and releases its security interest in the Released Intellectual Property, and Assignor hereby assigns and transfers to Assignee, without any representation, warranty, or recourse whatsoever, Assignor's entire right, title, and interest in and to the Released Intellectual Property, effective as of the date set forth above.

Assignor hereby agrees to execute such further instruments and documents and perform such further acts as Assignee may deem necessary to secure to Assignee the rights herein conveyed.

ASSIGNOR:

SWK FUNDING LLC, a limited liability company, as Agent

By: SWK Holdings Corporation, its sole Manager


By: 
Name: Winston Black
Title: CEO

EXHIBIT A

Released Intellectual Property

Patents

Description	Application Number	Registration Number	Notes on Ownership
Treatment of Cystitis Like Systems with Chondroitin Sulfate Following Administration of a Challenge Solution		6,083,933 (07/04/2000)	Owner TRIBUTE PHARMACEUTICALS CANADA, INC. Security Interest SWK FUNDING LLC <u>Reel/Frame:</u> 030988/0171 <u>Recorded:</u> 08/08/2013
Cystitis Treatment with High Dose Chondroitin Sulfate		7,772,210 (08/10/2010)	Owner TRIBUTE PHARMACEUTICALS CANADA, INC. Security Interest SWK FUNDING LLC <u>Reel/Frame:</u> 030988/0171 <u>Recorded:</u> 08/08/2013
Systitis Treatment with High Dose Chondroitin Sulfate		8,084,441 (12/27/2011)	Owner TRIBUTE PHARMACEUTICALS CANADA, INC. Security Interest SWK FUNDING LLC <u>Reel/Frame:</u> 030988/0171 <u>Recorded:</u> 08/08/2013
Systitis Treatment with High Dose Chondroitin Sulfate		8,334,276 (12/18/2012)	Owner TRIBUTE PHARMACEUTICALS CANADA, INC. Security Interest SWK FUNDING LLC <u>Reel/Frame:</u> 030988/0171 <u>Recorded:</u> 08/08/2013

Description	Application Number	Registration Number	Notes on Ownership
Systitis Treatment with High Dose Chondroitin Sulfate		8,778,908 (07/15/2014)	Owner TRIBUTE PHARMACEUTICALS CANADA, INC. First Security Interest SWK FUNDING LLC <u>Reel/Frame:</u> 030988/0171 <u>Recorded:</u> 08/08/2013 Second Security Interest SWK FUNDING LLC <u>Reel/Frame:</u> 034102/0715 <u>Recorded:</u> 11/04/2014
Methods of Use of Fenofibric Acid		7,569,612 (08/04/2009)	Owner TRIBUTE PHARMACEUTICALS INTERNATIONAL, INC.
Methods of Use of Fenofibric Acid		7,741,373 (06/22/2010)	Owner TRIBUTE PHARMACEUTICALS INTERNATIONAL, INC.
Methods of Use of Fenofibric Acid		7,741,374 (06/22/2010)	Owner TRIBUTE PHARMACEUTICALS INTERNATIONAL, INC.
Methods of Use of Fenofibric Acid		7,915,247 (03/29/2011)	Owner TRIBUTE PHARMACEUTICALS INTERNATIONAL, INC.

Trademarks

Description	Serial Number	Registration Number	Notes on Ownership
<p style="text-align: center;">TRIBUTE PHARMACEUTICALS</p>	<p style="text-align: center;">86/006,574 (07/10/2013)</p>		<p>Owner TRIBUTE PHARMACEUTICALS CANADA, INC.</p> <p>First Security Interest SWK FUNDING LLC <u>Reel/Frame:</u> 5087/0877 <u>Recorded:</u> 08/08/2013</p> <p>Second Security Interest SWK FUNDING LLC <u>Reel/Frame:</u> 5092/0624 <u>Recorded:</u> 08/16/2013</p> <p>Third Security Interest SWK FUNDING LLC <u>Reel/Frame:</u> 5394/0163 <u>Recorded:</u> 11/04/2014</p>
<p style="text-align: center;">TRIBUTE PHARMACEUTICALS</p>	<p style="text-align: center;">86/006,569 (07/10/2013)</p>		<p>Owner TRIBUTE PHARMACEUTICALS CANADA, INC.</p> <p>First Security Interest SWK FUNDING LLC <u>Reel/Frame:</u> 5087/0877 <u>Recorded:</u> 08/08/2013</p> <p>Second Security Interest SWK FUNDING LLC <u>Reel/Frame:</u> 5092/0624 <u>Recorded:</u> 08/16/2013</p> <p>Third Security Interest SWK FUNDING LLC <u>Reel/Frame:</u> 5394/0163 <u>Recorded:</u> 11/04/2014</p>
<p style="text-align: center;">FIBRICOR</p>		<p style="text-align: center;">3,729,598 (12/22/2009)</p>	<p>Owner TRIBUTE PHARMACEUTICALS INTERNATIONAL, INC.</p>
<p style="text-align: center;">URACYST</p>		<p style="text-align: center;">2,677,199 (01/21/2003)</p>	<p>Owner TRIBUTE PHARMACEUTICALS CANADA, INC.</p> <p>First Security Interest SWK FUNDING LLC <u>Reel/Frame:</u> 5087/0877</p>

Description	Serial Number	Registration Number	Notes on Ownership
			<u>Recorded:</u> 08/08/2013 Second Security Interest SWK FUNDING LLC <u>Reel/Frame:</u> 5092/0624 <u>Recorded:</u> 08/16/2013